[go: up one dir, main page]

WO2003033658A3 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents

Neutrokine-alpha et variant d'epissage de neutrokine-alpha Download PDF

Info

Publication number
WO2003033658A3
WO2003033658A3 PCT/US2002/032910 US0232910W WO03033658A3 WO 2003033658 A3 WO2003033658 A3 WO 2003033658A3 US 0232910 W US0232910 W US 0232910W WO 03033658 A3 WO03033658 A3 WO 03033658A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutrokine
alpha
methods
alphasv
antibodies
Prior art date
Application number
PCT/US2002/032910
Other languages
English (en)
Other versions
WO2003033658A2 (fr
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Michael W Laird
Stephen Ullrich
Original Assignee
Human Genome Sciences Inc
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Michael W Laird
Stephen Ullrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A Rosen, Michael W Laird, Stephen Ullrich filed Critical Human Genome Sciences Inc
Priority to EP02786413A priority Critical patent/EP1507793A4/fr
Priority to CA002476675A priority patent/CA2476675A1/fr
Priority to AU2002351495A priority patent/AU2002351495A1/en
Publication of WO2003033658A2 publication Critical patent/WO2003033658A2/fr
Publication of WO2003033658A3 publication Critical patent/WO2003033658A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des molécules d'acide nucléique codant Neutrokine-alpha et/ou des polypeptides de Neutrokine-alphaSV, et contenant des formes solubles du domaine extracellulaire. L'invention concerne aussi Neutrokine-alpha et/ou des polypeptides de Neutrokine-alphaSV, ainsi que vecteurs, des cellules hôtes et des procédés recombinants de fabrication correspondants. Cette invention a également trait à des anticorps ou à des portions d'anticorps qui se lient de manière spécifique à Neutrokine-alpha et/ou à Neutrokine-alphaSV, ainsi qu'à des procédés diagnostiques et thérapeutiques utilisant ces anticorps. L'invention se rapporte aussi à des procédés diagnostiques de détection de troubles liés au système immunitaire et à des procédés thérapeutiques de traitement de troubles liés au système immunitaire au moyen des compositions selon l'invention.
PCT/US2002/032910 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha WO2003033658A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02786413A EP1507793A4 (fr) 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha
CA002476675A CA2476675A1 (fr) 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU2002351495A AU2002351495A1 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32950801P 2001-10-17 2001-10-17
US60/329,508 2001-10-17
US32974701P 2001-10-18 2001-10-18
US60/329,747 2001-10-18
US33083501P 2001-10-31 2001-10-31
US60/330,835 2001-10-31
US33147801P 2001-11-16 2001-11-16
US60/331,478 2001-11-16
US33672601P 2001-12-07 2001-12-07
US60/336,726 2001-12-07
US36854802P 2002-04-01 2002-04-01
US60/368,548 2002-04-01

Publications (2)

Publication Number Publication Date
WO2003033658A2 WO2003033658A2 (fr) 2003-04-24
WO2003033658A3 true WO2003033658A3 (fr) 2004-05-27

Family

ID=27559746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032910 WO2003033658A2 (fr) 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Country Status (4)

Country Link
EP (1) EP1507793A4 (fr)
AU (1) AU2002351495A1 (fr)
CA (1) CA2476675A1 (fr)
WO (1) WO2003033658A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EP2281843B1 (fr) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B (BLyS)
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
WO2006044582A2 (fr) 2004-10-13 2006-04-27 The Washington University Utilisation de baff dans le traitement du sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
RU2436796C9 (ru) 2006-05-30 2013-12-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
DK2565206T3 (en) 2007-10-30 2016-06-06 Genentech Inc Antibody Purification by cation exchange chromatography
CN102149724B (zh) 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
WO2010030670A2 (fr) 2008-09-10 2010-03-18 Genentech, Inc. Compositions et procédés permettant d’éviter la dégradation oxydative des protéines
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
CN108892706A (zh) 2011-12-22 2018-11-27 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
CN110176272B (zh) * 2019-04-18 2021-05-18 浙江工业大学 一种基于多序列联配信息的蛋白质二硫键预测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334309A (en) * 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MACKAY ET AL.: "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations", J. EXP. MED., vol. 190, no. 11, 6 December 1999 (1999-12-06), pages 1697 - 1710, XP000915435 *
MOORE ET AL.: "BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, vol. 285, 9 July 1999 (1999-07-09), pages 260 - 263, XP002142252 *
NARDELLI ET AL.: "B lymphocyte stimulator (BLyS): A therapeutic trichotomy for the treatment of B lymphocyte diseases", LEUKEMIA AND LYMPHOMA, vol. 43, no. 7, 2002, pages 1367 - 1373, XP002973536 *
SCHNEIDER ET AL.: "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth", J. EXP. MED., vol. 189, no. 11, 17 June 1999 (1999-06-17), pages 1747 - 1756, XP000915409 *
See also references of EP1507793A4 *
WARE ET AL.: "APRIL and BAFF connect autoimmunity and cancer", J. EXP. MEDICINE, vol. 192, no. 11, 2000, pages F35 - F37, XP002224635 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations

Also Published As

Publication number Publication date
WO2003033658A2 (fr) 2003-04-24
AU2002351495A1 (en) 2003-04-28
CA2476675A1 (fr) 2003-04-24
EP1507793A2 (fr) 2005-02-23
EP1507793A4 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
WO2002018620A3 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2003033658A3 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2007123765A3 (fr) NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
WO2002008284A3 (fr) Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
WO2002000690A3 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
WO2001055367A8 (fr) Acides nucleiques, proteines et antigenes
WO2005056600A3 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
WO2001055317A8 (fr) Acides nucleiques, proteines et anticorps
WO2000053753A3 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
WO2000053757A3 (fr) Activation et inhibition de l'angiogenese et de la cardiovascularisation
WO2000053752A3 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
WO2002026781A3 (fr) Antagonistes du recepteur d'ige
WO2001025433A3 (fr) Nouveaux polypeptides, leurs acides nucleiques et leurs procedes d'utilisation dans l'angiogenese et la vascularisation
WO2001040464A8 (fr) Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation
AU5441200A (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2004020591A3 (fr) Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides
WO2002044366A3 (fr) Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379
WO2001055300A8 (fr) Acides nucleiques, proteines et anticorps
WO2001000662A3 (fr) Utilisation de polypeptides fgh-8 humains comme agents neurotrophiques
WO2004039952A3 (fr) Procedes d'utilisation de polypeptides humains codes par des polynucleotides
WO2004046310A3 (fr) Nouveaux polypeptides de souris codes par des polynucleotides et leurs procedes d'utilisation
WO2001055313A8 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2476675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002786413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002786413

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002786413

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)